A Phase 1-2 Study of the Safety, Pharmacokinetics, and Activity of ASTX029 in Subjects With Advanced Solid Tumors
Location: CPMC (San Francisco)
Please contact: email@example.com about study ASTX029
This trial is open for patientswith one of the following, for whom standard approved therapies are notavailable.
Cohort A: NRAS-mutant melanoma.
Cohort B: KRAS-mutant or KRAS-amplified non-small cell lung cancer (NSCLC).
Cohort C: BRAF V600-mutant cancers (non-colorectal cancers).
Cohort D: BRAF-fusion cancers.
Cohort E: Gynecological cancers with alterations in the MAPK pathway.
Cohort F: Tumors characterized by other gene aberrations that upregulate theMAPK signal pathway.